The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...

The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet ...

Teos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage ...

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...

GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, ...